Most Relevant Terms per Topic

Abstracts with Biological Entities (English) - 75 Topics / Sub-Topic Model 28

Topic 1 Topic 2 Topic 3 Topic 4 Topic 5 Topic 6 Topic 7 Topic 8 Topic 9 Topic 10 Topic 11 Topic 12 Topic 13 Topic 14 Topic 15
1 diagnostic % xtag patients microbiology COVID-19 % culture antibodies mers-cov POCT influenza dogs filmarray TAC
2 diagnosis samples assay BAL virology sars-cov-2 flu respiratory igg laboratories POC H1N1 rotavirus RP PLEX-ID
3 tests results multiplex antibiotic sequencing testing influenza respiratory viruses EIA EQA utilization legionnaires electron filmarray rp blood
4 molecular positive RVP pneumonia introduced false RSV viruses monoclonal quality care legionnaires' disease EM LDT respanel
5 infections study respiratory antibiotics techniques pooling 95 ad PEDV east laboratory pandemic agglutination fusion microarray
6 methods sensitivity viruses adults biology prevalence CI DFA rabies middle ED weighted microscopy panel biochemical
7 clinical performance % microbiological NA pandemic xpert cell culture serological external dengue ridts ELISA eplex ureaplasma
8 pathogens tested RV16 testing extraction pool - nasopharyngeal aspirates proteins syndrome healthcare seasonal canine panther blood culture
9 detection compared luminex atypical preparation group 100 aspirates sera middle east respiratory syndrome coronavirus devices score MAT RV+ susceptibility
10 infectious detection nxtag days mngs pooled A&B cell recombinant assessment point disease faecal filmarray respiratory panel MALDI-TOF/MS
11 rapid negative virus < nucleic individuals alere immunofluorescence serological assays upe decision 2009 electron microscopy biofire pcr assays
12 assays test RV unnecessary clinical virology positive specificity conventional TR-FIA LASV savings legionella leptospirosis flua array
13 techniques design panel yield internal CT flu a RT-PCR/ESI-MS monoclonal antibodies in-house pocts avian disorders RAD simultaneous
14 important background seeplex impact NGS strategy NPV viral culture igm participants pcr.ai swine tsutsugamushi nxtag‐rpp sepsis
15 diseases analytical advansure episodes EBV acid sensitivity maripoc antigens korea lab H3N2 latex verigene genes
16 viral 100 fast asthma technological approach confidence nats porcine SARS diagnostic accuracy ilis feline inc. PCR-ESI/MS
17 review evaluated RV15 ARI DNA probability ™ hmpv immunoassays orf1a reporting winthrop-university PCI PP phenotypic
18 amplification conclusions FTD bacteria characterization 2019 TB shell ELISA MERS trends triad BCV RP2 hominis
19 specific specificity PCR prescription clinical covid-19 pandemic allplex vial virus coronavirus staff point intestinalis FARP FTDRP21
20 agents objectives v2 CCQ advanced false negatives PPV r-mix antibody correctly utilization management division cats RF‐22 spectrometry
21 accurate assay rhinovirus outcome made RT-PCR confidence interval syncytial neutralization in-house assays physicians influenza-like O. EI fungi
22 development detected II PJ-CMV amplification size smear children pigs survey access H7N9 foetus rp panel identification
23 laboratory study design adenovirus CAP field current interval pediatric zika saudi making diagnostic legionnaires' disease triad faecal samples respiratory pathogens pathogens
24 patient PCR seegene 50 quality population flu b viral GICA saudi arabia — departments enzyme-linked ® emag
25 diagnostic tests rapid human symptoms introduce suspected A+B flow PCV2 proficiency database circulating immunochromatography salt m. hominis
26 disease clinical parainfluenza period molecular negatives binaxnow antigen belisa participating confirmation influenza-positive samples immunosorbent lake customized
27 infection high respiratory viruses immunocompromised sample large TAT RPII PRRSV arabia complexity influenza-positive clinical signs idaho tacs
28 diagnostics 2 anyplex exacerbation molecular diagnostics nucleic cepheid PCR/ESI‐MS RDT assurance cartridge-based swine influenza o. tsutsugamushi coinfections bloodstream infections
29 infectious diseases obtained detected FA‐RP automation acute respiratory syndrome coronavirus 2 LAMP conventional methods sars-cov phase united states swine influenza h1n1 pneumonia G. salt lake city bloodstream
30 nucleic assays metapneumovirus exacerbations technologies sars-cov-2 infection TB-LAMP viral isolation serum RNA data resulting fecal laboratory-developed ldts
31 surveillance predictive percent associated with costs pools 99.6 virus exposure 2012 cost pneumonia g. intestinalis hr concordance
32 based kits monoplex pulmonary introduction false negative influenza a CC FMIA quality assessment primary hospital typhi rhinovirus/enterovirus led
33 recent determined RPP adult control microg/g near-patient cytometry ielisa mers‐cov physician diagnostic t. foetus ANM‐PCR culture
34 acid confirmed hundred bacterial acid false positives NAT respiratory syncytial virus developed achieve tests 's T. forensic mass
35 advantages observed prospectively PCR examples coronavirus disease 2019 CI(95 nasopharyngeal immunoassay mers-cov rna input antigen tests bovine sample-to-answer 48
36 include comparison assays lavage universal coronavirus RP1 pneumovir nucleoprotein improvement rules influenza infection sucrose xpt CNSI
37 advances real-time RV12 febridx culture techniques test POC-PCR clart hepatitis clinical laboratories discontinuation diagnostic weighted point score system R. ciab CHAMPS
38 challenges conclusion FAST department diagnostic microbiology group testing SDB flow cytometry enzyme countries appearance caps radioimmunoassay bacterial VZV
39 future specimens H1 immunosuppressed interest RT-LAMP SPX direct serological diagnosis PTP acquired influenza diagnostic tests BRSV time plate
40 increasingly method specimens prescribing clinical setting NTS proflu isolation zika rdt gaps metrics clinical syndromic diagnosis in-practice pathogens SM
41 emerging > ® significantly relevance covid-19 testing al-flu shell vial biotin-eia inhibition OBJECTIVE winthrop-university hospital RPA respiratory strip-tube
42 timely ranged NL63 = turn window reference consensus demonstration MN privacy extrapulmonary r. typhi systems platform
43 testing limit subtyping treatment RNA cases FLUAV lines neutralizing realstar VL A(H1N1 immunochromatography test isolation targets
44 tools excellent all16 viral sequence-based single LIAT rtis tr-fias copies/reaction test older adults intestinal PIV3 pathogen
45 risk respifinder RT‐PCR march synthetic tests proflu plus spain 98.2 confirmatory point-of-care influenza virus infection CPV antibacterial/antiviral cards
46 applications 7 custom underwent classical images near-patient assays antibody seromp quality assurance present h1n1 pneumonia signs carlsbad ELECTRONIC
47 approaches analytical performance HKU1 jirovecii metagenomic sizes 1.00 tract hcov-19 amendments biothreat agents system FIP rsvs aetiological
48 respiratory cross-reactivity results pj-cmv pcr laboratories chance 0.83 pcr/esi‐ms assay ICT capacity molecular platforms adults technique 1 sealed
49 discussed hbov1 samples pneumocystis molecular biology aor proflu+ cell lines biotin-eias outbreak prescribed antigen serogroup specimens bottles
50 discuss 11 95 acute virology laboratories sars-cov-2 igm swabs multiplex nats tool laboratory menu empiric test analysis authorized